THE WHAT, WHY AND HOW OF BAYESIAN CLINICAL-TRIALS MONITORING

被引：58

作者：

FREEDMAN, LS

SPIEGELHALTER, DJ

PARMAR, MKB

机构：

[1] ADDENBROOKES HOSP,MRC,INST PUBL HLTH,BIOSTAT UNIT,CAMBRIDGE CB2,ENGLAND

[2] MCR,CANC TRIALS OFF,CAMBRIDGE CB2 2BB,ENGLAND

来源：

STATISTICS IN MEDICINE | 1994年 / 13卷 / 13-14期

关键词：

D O I：

10.1002/sim.4780131312

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

We discuss the advantages and limitations of group sequential methods for monitoring clinical trials data. We describe a Bayesian approach, based upon the use of sceptical prior distributions, that avoids some of the limitations of group sequential methods. We illustrate its use with data from a trial of levamisole plus 5-Fluorouracil for colorectal cancer.

引用

页码：1371 / 1383

页数：13

共 16 条

[1]

Armitage P., 1989, J ROYAL STATISTICAL, V51, P334

[2]

FLEMING TR, 1989, J NATL CANCER I, V81, P18

[3] STOPPING RULES FOR CLINICAL-TRIALS INCORPORATING CLINICAL OPINION [J].